A gene therapy generated by a deep learning search for the neural circuits controlling pain may provide a non-addictive form of pain management.

The study, published in the scientific journal Nature in January, is based on experiments conducted on mice by researchers at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. The researchers found the neural circuits that morphine acts upon to reduce pain.

The researchers explain their targeting of the anterior cingulate cortex (ACC) for response to morphine:

[We] show that a population of cingulate neurons encodes spontaneous pain-related behaviours and is selectively modulated by morphine… [We] built a biologically inspired chemogenetic gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic μ-opioid receptor promoter to drive inhibition.

If I understand the research correctly, they created a gene therapy that mimics the pain relief capabilities of opiates with zero addictive side effects. Which means patients would be able to self-administer painkillers for chronic pain. Or, as the researchers put it:

[…] offering a new strategy for precision pain management that targets a key nociceptive cortical opioid circuit with safe, on-demand analgesia.

“Safe, on-demand analgesia.” That would be something! Let’s take a closer look.

First, the study is preclinical. The gene therapy has not been tested in human beings, only in mice. The next step will be clinical trials.

Researchers used information gathered from the displacement behavior of mice. “The unpleasantness of pain drives motivational licking, which then reduces pain, forming a negative feedback loop,” write the researchers. The researchers traced the paw-licking behavior to the ACC, then monitored changes to paw-licking behavior with the introduction of morphine.

“[N]ext [we] sought to mimic these effects through a targeted chemogenetic gene therapy approach,” write the researchers. The researchers first discovered that they could reduce the experience of pain. Then they tested to see if the gene therapy would reduce the experience of chronic pain “without inducing tolerance.”

The ability to turn off chronic pain without resulting in addiction was then tested on both injured and healthy mice. They found no impacts on the healthy mice, and no dependency for the injured mice once they were healed.

In what could be a game-changer in pain management, the researchers conclude that “Our study demonstrates the therapeutic potential of targeting defined cortical ensembles for precision pain relief.” They have found a switch that shuts down pain and displacement without becoming habit-forming:

[We] silenced this circuit, successfully reproducing the analgesic effects of morphine while avoiding the sensory, tolerance and reinforcement effects.

An article in ScienceDaily says, “The findings could offer new hope to more than 50 million Americans living with chronic pain.” ScienceDaily says the research took over six years to complete and involved funding from the National Institutes of Health Director’s New Innovator Award, which is specifically designed for preclinical research.

The next phase is to move toward clinical trials with the Department of Neuroscience at the Perelman School of Medicine. It’s possible the researchers may have found a switch that reduces any compulsive behavior related to pain management. It is the sort of research unlikely to be funded by drug companies and would probably not happen without the government’s dedication to science for the public good.

Written by Steve O’Keefe. First published April 17, 2026.

Sources:

“This new therapy turns off pain without opioids or addiction,” ScienceDaily, March 28, 2026.

“Gene therapy ‘switch’ may offer non-addictive pain relief,” Penn Medicine, January 7, 2026.

“Mimicking opioid analgesia in cortical pain circuits,” Nature, January 7, 2026.

Image Copyright: peopleimages12.